{"schema_version":"secwatch.filing_event.v1","accession":"0000872589-25-000017","form_type":"8-K","ticker":"REGN","cik":"0000872589","company_name":"REGENERON PHARMACEUTICALS, INC.","filed_at":"2025-08-01T23:59:59+00:00","discovered_at":"2026-05-14T18:02:46.531518+00:00","generated_at":"2026-05-17T22:01:28.814532+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Regeneron Q2 revenue $3.68B (+4%), GAAP EPS $12.81, non-GAAP EPS $12.89; Dupixent sales +22%","bullets":["Revenue $3.676B (+4% YoY); GAAP net income $1.392B, GAAP EPS $12.81 (+3%); non-GAAP EPS $12.89 (+12%).","Dupixent global net sales (Sanofi) up 22% to $4.34B; EYLEA HD U.S. net sales up 29% to $393M, total EYLEA U.S. down 25% to $1.15B.","FDA approved Lynozyfic (linvoseltamab) for relapsed/refractory multiple myeloma and Dupixent for bullous pemphigoid and chronic spontaneous urticaria.","EYLEA HD PDUFA delayed due to FDA filler inspection; odronextamab received CRL; company expects expeditious resolution.","In-licensed late-stage dual GLP-1/GIP agonist from Hansoh; Q2 share repurchases $1.07B; $0.88 dividend declared."],"urls":{"canonical":"https://secwatch.observer/filing/0000872589-25-000017","json":"https://secwatch.observer/filing/0000872589-25-000017.json","markdown":"https://secwatch.observer/filing/0000872589-25-000017.md","text":"https://secwatch.observer/filing/0000872589-25-000017.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/872589/000087258925000017/0000872589-25-000017-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/872589/000087258925000017/regn-20250801.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T22:01:28.814532+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}